As global markets navigate a landscape marked by trade negotiations and economic uncertainty, Asia's financial scene remains a focal point for investors seeking opportunities amid evolving conditions. Penny stocks, though an older term, still capture the essence of investing in smaller or emerging companies that can offer significant value. By focusing on those with strong financials and potential growth paths, investors may uncover hidden gems within this segment of the market. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Advice IT Infinite (SET:ADVICE) THB4.90 THB3.04B ★★★★★★ T.A.C. Consumer (SET:TACC) THB4.58 THB2.75B ★★★★★★ Tirathai (SET:TRT) THB3.18 THB979.47M ★★★★★☆ CNMC Goldmine Holdings (Catalist:5TP) SGD0.41 SGD166.17M ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.186 SGD37.05M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.21 SGD8.7B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.12 HK$47.17B ★★★★★★ Lever Style (SEHK:1346) HK$1.17 HK$738.21M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.38 HK$2.3B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.18 HK$1.82B ★★★★★★ Click here to see the full list of 1,174 stocks from our Asian Penny Stocks screener. Let's review some notable picks from our screened stocks. Viva Biotech Holdings Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Viva Biotech Holdings is an investment holding company that provides structure-based drug discovery services to biotechnology and pharmaceutical customers globally, with a market cap of HK$3.37 billion. Operations: The company's revenue is primarily derived from its Drug Discovery Services, which generated CN¥821.31 million, and its Contract Development Manufacture Organisation (CDMO) and Commercialisation Services, contributing CN¥1.18 billion. Market Cap: HK$3.37B Viva Biotech Holdings has shown a significant turnaround, reporting a net income of CN¥167.29 million for 2024, compared to a loss the previous year. The company's revenue streams are primarily from Drug Discovery Services and CDMO services, totaling CN¥1.99 billion. Despite high share price volatility and an increased debt-to-equity ratio over five years, its debt is well covered by operating cash flow and interest payments are adequately managed with EBIT coverage of 6.9 times. Recent board changes aim to enhance governance amid improving operational efficiency and investment gains contributing to profitability recovery. Click here and access our complete financial health analysis report to understand the dynamics of Viva Biotech Holdings. Evaluate Viva Biotech Holdings' prospects by accessing our earnings growth report. Story Continues SEHK:1873 Debt to Equity History and Analysis as at May 2025 Tian An China Investments Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Tian An China Investments Company Limited is an investment holding company that focuses on investing in, developing, and managing properties in the People's Republic of China, Hong Kong, and the United Kingdom with a market cap of HK$6.45 billion. Operations: The company's revenue segments include Healthcare (HK$1.58 billion), Property Investment (HK$583.52 million), and Property Development (HK$520.46 million). Market Cap: HK$6.45B Tian An China Investments has experienced a challenging fiscal year, reporting a net loss of HK$207.08 million for 2024, contrasting with the previous year's profit of HK$1.22 billion. The downturn is attributed to reduced revenue from property sales and lower recognition due to fewer project handovers amid a sluggish Mainland property market. Despite these challenges, the company maintains strong asset coverage with short-term assets exceeding liabilities and more cash than total debt. Its seasoned management and board provide stability as they navigate current market conditions, while recent dividend adjustments reflect ongoing financial recalibrations. Click to explore a detailed breakdown of our findings in Tian An China Investments' financial health report. Explore historical data to track Tian An China Investments' performance over time in our past results report.SEHK:28 Debt to Equity History and Analysis as at May 2025 Frencken Group Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Frencken Group Limited is an investment holding company that offers original design, original equipment, and diversified integrated manufacturing solutions globally, with a market cap of SGD478.34 million. Operations: The company's revenue is primarily generated from its Mechatronics segment, which accounts for SGD706.09 million, followed by the Integrated Manufacturing Services (IMS) segment at SGD85.68 million, and Investment Holding & Management Services contributing SGD11.53 million. Market Cap: SGD478.34M Frencken Group Limited's financial health is characterized by solid asset coverage, with short-term assets of SGD539.8 million surpassing both short- and long-term liabilities. The company has demonstrated stable earnings growth, reporting a net income increase to SGD37.12 million for 2024 from the previous year, alongside a dividend declaration of SGD0.0261 per share payable in May 2025. Despite its low Return on Equity at 8.4%, Frencken's interest payments are well-covered by EBIT, and its debt levels are manageable with more cash than total debt, reflecting prudent financial management amidst modest profit margin improvements and stable weekly volatility. Unlock comprehensive insights into our analysis of Frencken Group stock in this financial health report. Explore Frencken Group's analyst forecasts in our growth report.SGX:E28 Debt to Equity History and Analysis as at May 2025 Taking Advantage Access the full spectrum of 1,174 Asian Penny Stocks by clicking on this link. Interested In Other Possibilities? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1873 SEHK:28 and SGX:E28. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
Viva Biotech Holdings Leads The Charge In Asian Penny Stocks
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...